v3.23.2
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
 1 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 12, 2022
Dec. 31, 2022
Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]              
Financial Designation, Predecessor and Successor [Fixed List] Successor Successor Successor Predecessor Predecessor Successor Predecessor
Total potentially dilutive shares   11,991,694 12,104,694        
Warrant [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   [1] [2]   8,560,561 [1]   2,154,351 [1]
Successor Warrant [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   8,628,695 [1],[3] 8,628,695 [2],[4]    
Predecessor Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares          
Successor Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares     2,106,235        
Series A Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   863,500 [5] 863,500 [6]        
Series B Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   506,264 [7] 506,264 [8]        
Convertible Notes Payable [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   [9] [10]        
Share-Based Payment Arrangement, Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares   1,993,235          
Predecessor Series A Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares            
Predecessor [Member]              
Reorganization, Chapter 11 [Line Items]              
Financial Designation, Predecessor and Successor [Fixed List]       Predecessor Predecessor   Predecessor
Total potentially dilutive shares       15,828,891 25,006,119   14,309,717
Predecessor [Member] | Warrant [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares       2,154,352 [2] 8,560,561   2,154,351
Predecessor [Member] | Successor Warrant [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares       [2],[4] [1],[3]   [1],[3]
Predecessor [Member] | Predecessor Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares       9,947,968 10,039,348   8,755,179
Predecessor [Member] | Successor Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares            
Predecessor [Member] | Series A Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares        
Predecessor [Member] | Series B Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares        
Predecessor [Member] | Convertible Notes Payable [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares       3,726,571 [10] [9]   3,400,187 [9]
Predecessor [Member] | Share-Based Payment Arrangement, Option [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares          
Predecessor [Member] | Predecessor Series A Convertible Preferred Stock [Member]              
Reorganization, Chapter 11 [Line Items]              
Total potentially dilutive shares         6,406,210  
[1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 Predecessor or 119,125 Successor shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.
[2] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 Predecessor or 119,125 Successor shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 7 - Commitments and Contingencies - License Agreements for details.
[3] Does not include an additional 3,454,000 shares if the Successor Series A warrant exercise price resets to its floor price.
[4] Does not include an additional
[5] Does not include an additional 3,454,000 shares if the Successor Series A Convertible Preferred Stock conversion price resets to its floor price.
[6] Does not include an additional 3,454,000 shares if the Successor Series A Convertible Preferred Stock conversion price resets to its floor price of $2.00 per share.
[7] Does not include an additional 216,970 shares if the Successor Series B Convertible Preferred Stock conversion price resets to its floor price.
[8] Does not include an additional 216,970 shares if the Successor Series B Convertible Preferred Stock conversion price resets to its floor price of $7.00 per share.
[9] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $3.25 per share as of December 31, 2021.
[10] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $3.00 per share as of March 31, 2022.